loading page

Brain Mineralocorticoid receptor in health and disease: from molecular signaling to cognitive and emotional function
  • +1
  • Susana Paul,
  • Katja Wingenfeld,
  • Christian Otte,
  • Onno Meijer
Susana Paul
Leiden University Medical Center

Corresponding Author:[email protected]

Author Profile
Katja Wingenfeld
Charité Universitätsmedizin Berlin Klinik für Geriatrie und Altersmedizin Campus Benjamin Franklin
Author Profile
Christian Otte
Charité Universitätsmedizin Berlin Klinik für Geriatrie und Altersmedizin Campus Benjamin Franklin
Author Profile
Onno Meijer
Leiden University Medical Center
Author Profile


Brain mineralocorticoid receptors (MR) mediate effects of aldosterone in relation to salt homeostasis, and of glucocorticoid stress hormones corticosteroids in the context of stress adaptation. Brain stem MRs respond to aldosterone, while forebrain MRs mediate rapid and delayed MR-mediated glucocorticoids effects in conjunction with the glucocorticoid receptor. MR-mediated effects depend on gender, genetic variations and environmental influences. Disturbed MR activity by chronic stress or in certain (endocrine) diseases can cause deleterious effects on affective state, cognitive and behavioural function in susceptible individuals. High MR activation may have protective effects in healthy individuals, whereas dysregulated high MR activity during a stress response would require treatment with mineralocorticoid receptor antagonists (MRAs). Here, we discuss recent pharmacological and genetic developments, from the molecular underpinnings of MR signaling and function, to pharmacological interventions in the clinic. Improved understanding of MR dependent pathways will help to improve glucocorticoid therapy, unwanted side effects and psychiatric symptoms.
07 Oct 2021Submitted to British Journal of Pharmacology
11 Oct 2021Submission Checks Completed
11 Oct 2021Assigned to Editor
15 Oct 2021Reviewer(s) Assigned
03 Nov 2021Review(s) Completed, Editorial Evaluation Pending
07 Nov 2021Editorial Decision: Revise Minor
18 Feb 20221st Revision Received
23 Feb 2022Submission Checks Completed
23 Feb 2022Assigned to Editor
23 Feb 2022Reviewer(s) Assigned
07 Mar 2022Review(s) Completed, Editorial Evaluation Pending
08 Mar 2022Editorial Decision: Accept
Jul 2022Published in British Journal of Pharmacology volume 179 issue 13 on pages 3205-3219. 10.1111/bph.15835